40 completed, 4 terminated, 4 unknown, 3 withdrawn. 24 Phase 4, 11 Phase 3, 10 Phase 2, 3 Not applicable, 2 Phase 1.
Follow Fluvastatin: new trials by email Literature Review of Fluvastatin trials Research Report on Fluvastatin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Inclisiran Versus Statin for Primary Aldosteronism inclisiran, Lipophilic statins (such as Simvastatin, Atorvastatin, Fluvastatin, Lovastatin,Pitavastatin), Spironolactone (drug) - Primary Aldosteronism | Not applicable | Recruiting | Third Military Medical University | 50 | 2026-10-01 | 2026-10-21 |
| StAtins in Frail OldEr Patients with Ischemic Stroke or Transient Ischemic Attack - the Randomized Controlled Trial Statin (atorvastatin, fluvastatin, pravastatin, rosuvastatin or simvastatin) - Ischemic Stroke, Transient Ischemic Attack | Phase 4 | Not yet recruiting | Prof. dr. Nathalie van der Velde | 612 | 2025-02-01 | 2025-01-21 |
| Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study Statin - Ischemic Stroke, TIA | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 300 | 2024-11-01 | 2025-01-21 | |
| Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas Fluvastatin, RNA-sequencing, Gene expression profiling - Malignant Melanoma | Early Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2020-11-06 | 2020-07-27 | |
| Drug-Drug Interaction Between Rifampin and Fluvastatin rifampin IV, Rifadin 300Mg Capsule, Fluvastatin 20 MG - Drug-drug Interaction | Phase 4 | Completed | University of California, San Francisco | 10 | 2019-04-25 | 2021-09-08 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Atorvastatin, Simvastatin - Hypercholesterolemia | Phase 3 | Completed | Sanofi | 18 | 2018-08-31 | 2020-12-29 |
| An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Alirocumab SAR236553 (REGN727), Rosuvastatin, Atorvastatin - Hypercholesterolaemia | Phase 3 | Completed | Sanofi | 153 | 2018-05-31 | 2023-05-06 |
| Effect of Fluvastatin on Brown Fat Activity Fluvastatin - Adipose Tissue, Brown, Insulin Resistance | Phase 4 | Completed | University of Zurich | 17 | 2017-05-31 | 2018-05-31 |
| Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination fluvastatin 10 mg and valsartan 20 mg, placebo - Atherosclerosis | Not applicable | Completed | University Medical Centre Ljubljana | 20 | 2014-09-01 | 2018-01-08 |
| Safety of Fluvastatin-Celebrex Association in Low-grade and High Grade Optico-chiasmatic Gliomas Fluvastatine, Celebrex - Glioma | Phase 1 | Completed | Centre Oscar Lambret | 20 | 2014-06-01 | 2026-03-18 |
| Novel Window of Opportunity Trial to Evaluate the Impact of Statins to Oppose Prostate Cancer Fluvastatin, Pimonidazole - Prostate Cancer | Phase 2 | Completed | University Health Network, Toronto | 33 | 2014-02-01 | 2017-10-26 |
| A Study of LY3015014 in Participants With High Cholesterol LY3015014, Placebo, Statin - Hypercholesterolemia | Phase 2 | Completed | Eli Lilly and Company | 527 | 2013-06-01 | 2019-09-18 |
| Optimal Blood Pressure and Cholesterol Targets for Preventing Recurrent Stroke in Hypertensives all approved antihypertensive drugs; all approved statins - Stroke, Transient Ischemic Attack | Phase 4 | Completed | Istituto Auxologico Italiano | 200 | 2013-04-01 | 2024-02-20 |
| Statin Recapture Therapy Before Coronary Artery Bypass Grafting Statin Recapture Therapy, Placebo - Coronary Artery Disease | Phase 4 | Completed | University of Cologne | 2630 | 2012-11-07 | 2022-07-22 |
| High Potency Statins and the Risk of Diabetes Rosuvastatin (≥10 mg), Atorvastatin (≥20 mg), Simvastatin (≥40 mg) - Diabetes Mellitus, Type 2, Cardiovascular Disease | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 136966 | 2012-07-01 | 2016-03-14 | |
| Fluvastatin AmelIorates aTHerosclerosis Study Fluvastatin extended release tablet - Coronary Heart Disease, Atherosclerosis | Phase 4 | Unknown | Beijing Anzhen Hospital | 140 | 2012-07-01 | 2012-09-07 |
| Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Fluvastatin sodium - Lipid Metabolism Disorders | Phase 4 | Completed | Novartis Pharmaceuticals | 436 | 2012-01-01 | 2015-08-13 |
| High Potency Statins and Acute Kidney Injury Rosuvastatin (≥10 mg), Atorvastatin (≥20 mg), Simvastatin (≥40 mg) - Hypercholesterolemia | Completed | Canadian Network for Observational Drug Effect Studies, CNODES | 2067639 | 2011-01-01 | 2016-03-14 | |
| Intensive Statin Treatment in Chinese Coronary Artery Disease Patients Undergoing PCI Atorvastatin, Statin - Non-ST Segment Elevation Myocardial Infarction, Unstable Angina Pectoris | Phase 4 | Completed | Peking University First Hospital | 2884 | 2010-06-01 | 2013-04-30 |
| A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C Fluvastatin, Peginterferon alfa2a, ribavirin - Hepatitis C, Hepatitis C Virus | Phase 2 | Withdrawn | University of Chicago | 2010-02-01 | 2013-07-01 |
Showing 20 of 54. Sign in to see all of them.
Hypercholesterolemia (9) · Dyslipidemias (6) · Hypertension (5) · Coronary Disease (4) · Atherosclerosis (3) · Cardiovascular Diseases (3) · Hepatitis C (3) · Aortic Valve Stenosis (2) · Diabetes Mellitus, Type 2 (2) · Inflammation (2) · Ischemic Attack, Transient (2) · Ischemic Stroke (2) · Metabolic Syndrome (2) · Myocardial Infarction (2) · Acute Kidney Injury (1)
Novartis (10) · Novartis Pharmaceuticals (3) · University Hospital Schleswig-Holstein (3) · Bader, Ted, M.D. (2) · Canadian Network for Observational Drug Effect Studies, CNODES (2) · Mario Negri Institute for Pharmacological Research (2) · Sanofi (2) · University of California, San Francisco (2) · AORTICA Group (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Beijing Anzhen Hospital (1) · Case Comprehensive Cancer Center (1) · Centre Oscar Lambret (1) · Corcept Therapeutics (1) · Eli Lilly and Company (1)
United States (12) · Germany (7) · Canada (6) · Spain (6) · China (5) · Italy (4) · Netherlands (4) · Russia (4) · Czechia (3) · Denmark (3) · Japan (3) · Switzerland (3) · Turkey (Türkiye) (3) · Austria (2) · Brazil (2)
Lutz Renders, MD (3) · Colin Dormuth, M.Sc., Sc.D. (2) · Nathalie van der Velde, Prof. dr. (2) · Alberto Zanchetti (1) · Alessandro Rossi, MD (1) · Angelo Branzi, MD (1) · Candido Martin-Luengo, MD, PhD (1) · Dennis Swearingen, MD (1) · Doruk Erkan, MD (1) · Dugald Seely, ND (1) · Erica Daina, MD (1)
PMID 18312764, PMID 18413332, PMID 18622282, PMID 19728082, PMID 20067513, PMID 20500832, PMID 20664903, PMID 20671225, PMID 23334870, PMID 23511950, PMID 23630244, PMID 24451612, PMID 24874977, PMID 24979303, PMID 26093863, PMID 29212965, PMID 32037254, PMID 32203069, PMID 32699996, PMID 32905623, PMID 33225717, PMID 36325897, PMID 36398903, PMID 38018702, PMID 38315470, PMID 41070271
2017 (2), 2004 (1), R01AG021570 (1)